SPK-9001: Additional Ph I/II data

Data from the first 9 hemophilia B patients in an open-label, dose-escalation, U.S. and Australian Phase I/II trial showed that a single dose of 5x1011 vg/kg IV SPK-9001 led to an asymptomatic, transi...